Hailong Li^1,#, Wen Ouyang^2,#, Yiyin Long¹, Yun Peng¹, Ziyi Liu¹, Qi Zhou¹, Rong Xu^1,*, Wei Du^1,*

Oncology Research, Vol.33, No.9, pp. 2549-2571, 2025, DOI:10.32604/or.2025.065050 - 28 August 2025

Abstract Background: The study aimed to explore the clinical value of mitochondrial ribosomal protein L18 (MRPL18) in breast cancer. Methods: Multiple databases were used to validate the expression of MRPL18. The prognostic impact and predictive value of MRPL18 were evaluated by using predictive models. Protein-protein interaction (PPI) networks were constructed by using GeneMANIA. Enrichment analysis is used to explore the signaling pathway regulated by MRPL18. Cell counting kit-8 (CCK-8) assays, colony formation, migration assays, flow cytometry, and xenograft models were employed to evaluate the role of MRPL18 in tumor progression. The immune response of MRPL18 was More >

LUCIANA SABOYA^1,2, KEINI BUOSI¹, TIAGO SILVA², ELAINE CANDIDO¹, JOSIANE MORARI³, LICIO A. VELLOSO³, SHAHROKH F. SHARIAT^4,5,6,7, MARCUS V. SADI², LEONARDO O. REIS^1,8,9,*

Oncology Research, Vol.33, No.6, pp. 1495-1503, 2025, DOI:10.32604/or.2025.061812 - 29 May 2025

Abstract Objective: To determine the safety and the role of modulating cytokines and proteases in the immune response to intravesical Bacillus Calmette-Guérin (BCG) when primed with systemic intradermal BCG. Methods: Phase 1 and mechanistic longitudinal, prospective, single-blind randomized study (NCT04806178). Twenty-one non-muscle invasive urothelial bladder cancer patients undergoing intravesical adjuvant BCG after transurethral resection of bladder tumor (TURBT) in a teaching hospital between September 2021 and April 2023 were randomized to 0.1 mL of intradermal BCG vaccine or placebo (0.9% saline) administered 15 days before the start of intravesical BCG therapy. Blood samples were evaluated mechanistically… More >

HAISU LIANG^1,2,#, WEI YAN^3,#, ZHI LIU^1,4, YUNBO HE^1,2,5, JIAO HU¹, ZHIWEI SHU¹, HUIHUANG LI¹, BELAYDI OTHMANE¹, WENBIAO REN^1,6, CHAO QUAN¹, DONGXU QIU¹, MINFENG CHEN¹, WEI XIONG⁵, BINGNAN ZHANG^1,*, PEIHUA LIU^1,2,*

Oncology Research, Vol.33, No.5, pp. 1105-1119, 2025, DOI:10.32604/or.2024.054623 - 18 April 2025

Abstract Circular RNAs (circRNAs) are a type of non coding RNA that possess unique single stranded circular structures formed through reverse splicing mechanisms. Due to the lack of a free end that is typically susceptible to degradation by nucleases, circular RNAs exhibit resistance to ribonuclease R, making them highly stable in eukaryotic cells. The complex relationship between circRNA dysregulation and various pathophysiological conditions, especially cancer. Tumor microenvironment (TME) is a collective term for various components surrounding tumors and is an important factor affecting tumor development. Simultaneous infiltration of TME by different types of immune cells; These… More >

TIANYUN ZHU^1,2,#, CUNYAN ZHAO^1,2,#, RUI GONG^1,2, AO QIAN¹, XIAOSHU WANG¹, FANGHUI LU², GANG HUO¹, LIANGJUN QIAO³, SONG CHEN^1,*

Oncology Research, Vol.33, No.2, pp. 431-442, 2025, DOI:10.32604/or.2024.050794 - 16 January 2025

Abstract Background: PLK3, which played an important role in cell cycle progression and stress response, was identified as highly expressed in various carcinomas. However, the functions, molecular characteristics, and prognostic value of PLK3 in glioma remained unexplored. Methods: We analyzed PLK3 expression in glioma samples from multiple databases. Both overexpression and knockdown of Plk3 were performed to investigate tumor cell growth in glioma, and the transplanted glioma mouse model demonstrated the role of Plk3 on tumor progression. Immunohistochemistry was conducted to detect PLK3 expression and immune cell infiltration. The trans-well assay for PLK3 on the immune… More >

WEIGANG REN^1,#, JING LI^2,#, RUIJIANG ZENG^3,4, LIANG ZHU^3,4,*

BIOCELL, Vol.48, No.9, pp. 1323-1330, 2024, DOI:10.32604/biocell.2024.051747 - 04 September 2024

Abstract Background: Clear cell renal cell carcinoma (ccRCC) stands as the most prevalent form of kidney cancer, accounting for a significant proportion of malignancies affecting the kidneys. ccRCC is well known as a type of tumour with immunogenicity. Immune checkpoint inhibitors (ICIs) aim to enhance the anticancer immune response in ccRCC by blocking programmed cell death 1 ligand 1/programmed death 1 (PD-L1/PD-1) pathways. In a previous study, we showed that RING finger protein 26 (RNF26) degrades chromobox 7 (CBX7) to activate the tumor necrosis factor (TNF) in ccRCC. Methods: We analyzed The Cancer Genome Atlas (TCGA)… More > Graphic Abstract

SHUANGSHUANG ZENG^1,2, XI CHEN^1,2, QIAOLI YI^1,2, ABHIMANYU THAKUR³, HUI YANG^4,*, YUANLIANG YAN^1,2, SHAO LIU^1,2,*

Oncology Research, Vol.32, No.2, pp. 261-272, 2024, DOI:10.32604/or.2023.042345 - 28 December 2023

Abstract Finding biomarkers for immunotherapy is an urgent issue in cancer treatment. Cellular retinoic acid-binding protein 2 (CRABP2) is a controversial factor in the occurrence and development of human tumors. However, there is limited research on the relationship between CRABP2 and immunotherapy response. This study found that negative correlations of CRABP2 and immune checkpoint markers (PD-1, PD-L1, and CTLA-4) were observed in breast invasive carcinoma (BRCA), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD) and testicular germ cell tumors (TGCT). In particular, in SKCM patients who were treated with PD-1 inhibitors, high levels of CRABP2 predicted poor… More >

CARL RANDALL HARREL¹, VALENTIN DJONOV², ANA VOLAREVIC³, DRAGICA PAVLOVIC⁴, VLADISLAV VOLAREVIC^4,5,*

BIOCELL, Vol.47, No.8, pp. 1757-1769, 2023, DOI:10.32604/biocell.2023.028567 - 28 August 2023

Abstract Exosomes derived from mesenchymal stem cells (MSC-Exos) are nano-sized extracellular vesicles enriched with bioactive molecules, such as microRNAs, enzymes, cytokines, chemokines, immunomodulatory, trophic, and growth factors. These molecules regulate the survival, phenotype, and function of malignant and tumor-infiltrated immune cells. Due to their nano-size and bilayer lipid envelope, MSC-Exos can easily bypass biological barriers and may serve as drug carriers to deliver chemotherapeutics directly into the tumor cells. Here, we summarize current knowledge regarding molecular mechanisms responsible for MSC-Exos-dependent modulation of tumor progression and discuss insights regarding the therapeutic potential of MSC-Exos in the treatment More > Graphic Abstract

MANSI SHRIVASTAVA¹, DIKSHA PANDEY¹, POONAM SHARMA², RAMBIR SINGH^3,*

BIOCELL, Vol.46, No.2, pp. 339-356, 2022, DOI:10.32604/biocell.2022.016822 - 20 October 2021

Abstract Aspergillus is a group of conidial fungi, isolated from soil and litter, cause serious diseases in humans and animals. This ubiquitous fungus is prevalent in the air and inhalation of fungal spores is common. Fungal diseases from Aspergillus became a major health problem and are difficult to manage because they tend to be chronic and invasive, hard to diagnose and difficult to exterminate with antifungal drugs. Although, immune responses play vital roles in monitoring the fate of fungal infections and regulation of the immune responses against fungal infections might be an effective approach for controlling and… More >

LINNA TAN^1,2, YUYONG TAN^1,2, DELIANG LIU^1,2,*

BIOCELL, Vol.44, No.4, pp. 535-543, 2020, DOI:10.32604/biocell.2020.09171 - 24 December 2020

Abstract ULK1 (unc-51 like autophagy activating kinase 1), a mammalian serine/threonine kinase, is a key component of autophagy initiation complex and helps to induce all types of autophagy. Canonical autophagy is a process in which, through the interactions of a series of autophagy-related proteins, damaged organelles or misfolded proteins are engulfed by autophagosomes and then merged with lysosomes to be degraded. Thus, canonical autophagy is an important constituent part of the cellular “quality control.” Besides, accumulating evidence indicates that ULK1 exerts autophagy-independent effects in a cell-specific manner. For example, ULK1 facilitates neurite elongation through the regulation More >

Ji SHI; Peixin SUN, Ye ZHANG, Bing YAO, Haozhe PIAO

BIOCELL, Vol.43, No.3, pp. 119-128, 2019, DOI:10.32604/biocell.2019.07577

Abstract Glioma is the most common primary malignant brain tumor with a poor survival rate. In recent years, no significant progress has been made in the treatment of gliomas in contrast to the development of improved diagnosis via molecular typing. Newcastle disease virus (NDV), a negative-stranded RNA virus that exhibits oncolytic activity, has been investigated for its capacity to elicit antitumor activity in many types of cancers, including glioma. Therefore, application of oncolytic viruses, such as NDV, as a new treatment strategy to specifically target aberrant signaling in glioblastomas has brought new hope. For many years, More >